A new Cochrane Review highlights the value of nurse-led titration of ACE inhibitors, beta-blockers and angiotensin II receptor blockers in patients with chronic heart failure. All-cause mortality and hospitalisations were lower in the nurse-led titration group compared with the usual care of titration by GPs.
Drugs used to treat diabetes could also be used to treat Alzheimer’s disease, and vice versa, according to new basic research from the University of Aberdeen. This is also the first study of its kind to show that Alzheimer’s disease can lead to diabetes, as opposed to diabetes occurring first as was previously thought.
Bariatric surgery on some obese patients with type 2 diabetes could result in lifetime savings of about £95,000 per patient, mostly due to reduced medication costs, according to data presented at the recent European Obesity Congress in Gothenburg, Sweden.
A 20-year study demonstrates that higher levels of cardiorespiratory fitness reduce the risk for developing prediabetes or diabetes. This is the longest study conducted in this area and provides strong evidence that supports the commonly accepted view that fitness is beneficial in reducing the risk for prediabetes and diabetes.
New data from the EMPA-REG OUTCOME and LEADER trials presented at the recent American Diabetes Association meeting show that the SGLT-2 inhibitor empagliflozin and the GLP-1 receptor analogue liraglutide significantly reduce cardiovascular mortality and cardiovascular events in high-risk type 2 diabetes patients.
This month’s Back to Basics feature is a free wallchart to aid interpretation of the NHS Health Check results. Use this information with last month’s Back to Basics NHS Health Check chart to raise your patients’ awareness of cardiovascular risk factors and to determine the best lifestyle and medical approaches for each individual.
The use of electronic cigarettes has been marked by huge growth in sales and ongoing controversy over their value in helping smokers to quit. This article originally published on our sister title – the Primary Care Cardiovascular Journal, discusses some of the key issues for primary healthcare professionals on this new technology.
New data show that after 3 years’ treatment with liraglutide, adults with obesity or who are overweight with comorbidities lost more weight, reduced blood pressure, triglycerides and cholesterol level compared with placebo.
Two new studies highlight the ongoing gap in life expectancy between people living with type 1 diabetes (T1D) and the general population.